JP2015534819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534819A5 JP2015534819A5 JP2015540872A JP2015540872A JP2015534819A5 JP 2015534819 A5 JP2015534819 A5 JP 2015534819A5 JP 2015540872 A JP2015540872 A JP 2015540872A JP 2015540872 A JP2015540872 A JP 2015540872A JP 2015534819 A5 JP2015534819 A5 JP 2015534819A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- nucleic acid
- genetically modified
- promoter
- acid encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 56
- 108020004707 nucleic acids Proteins 0.000 claims description 49
- 102000039446 nucleic acids Human genes 0.000 claims description 49
- 150000007523 nucleic acids Chemical class 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 24
- 108090001005 Interleukin-6 Proteins 0.000 claims description 22
- 102000004889 Interleukin-6 Human genes 0.000 claims description 22
- 201000005787 hematologic cancer Diseases 0.000 claims description 22
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 22
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 20
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 102000052611 human IL6 Human genes 0.000 claims description 13
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 12
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 12
- 101150036449 SIRPA gene Proteins 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000004083 survival effect Effects 0.000 claims description 7
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 6
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims description 6
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims description 6
- 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 claims description 6
- 102000000646 Interleukin-3 Human genes 0.000 claims description 6
- 108010002386 Interleukin-3 Proteins 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 101710113649 Thyroid peroxidase Proteins 0.000 claims description 6
- 102000046157 human CSF2 Human genes 0.000 claims description 6
- 102000055276 human IL3 Human genes 0.000 claims description 6
- 102000053400 human TPO Human genes 0.000 claims description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 230000011712 cell development Effects 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 13
- 102000025171 antigen binding proteins Human genes 0.000 claims 7
- 108091000831 antigen binding proteins Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 210000005260 human cell Anatomy 0.000 claims 6
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 claims 4
- 241000699670 Mus sp. Species 0.000 claims 4
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 210000000952 spleen Anatomy 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 238000003209 gene knockout Methods 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722437P | 2012-11-05 | 2012-11-05 | |
| US61/722,437 | 2012-11-05 | ||
| PCT/US2013/068569 WO2014071397A2 (en) | 2012-11-05 | 2013-11-05 | Genetically modified non-human animals and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018194712A Division JP6772234B2 (ja) | 2012-11-05 | 2018-10-16 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534819A JP2015534819A (ja) | 2015-12-07 |
| JP2015534819A5 true JP2015534819A5 (https=) | 2016-12-22 |
| JP6422441B2 JP6422441B2 (ja) | 2018-11-14 |
Family
ID=49876957
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540872A Active JP6422441B2 (ja) | 2012-11-05 | 2013-11-05 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2018194712A Active JP6772234B2 (ja) | 2012-11-05 | 2018-10-16 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2020165884A Active JP7105844B2 (ja) | 2012-11-05 | 2020-09-30 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2022111649A Active JP7579304B2 (ja) | 2012-11-05 | 2022-07-12 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2024187836A Pending JP2025010204A (ja) | 2012-11-05 | 2024-10-25 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018194712A Active JP6772234B2 (ja) | 2012-11-05 | 2018-10-16 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2020165884A Active JP7105844B2 (ja) | 2012-11-05 | 2020-09-30 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2022111649A Active JP7579304B2 (ja) | 2012-11-05 | 2022-07-12 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| JP2024187836A Pending JP2025010204A (ja) | 2012-11-05 | 2024-10-25 | 遺伝学的に修飾された非ヒト動物およびその使用法 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9901082B2 (https=) |
| EP (5) | EP3556206B1 (https=) |
| JP (5) | JP6422441B2 (https=) |
| KR (5) | KR102402806B1 (https=) |
| CN (3) | CN108401987B (https=) |
| AU (3) | AU2013337242B2 (https=) |
| CA (1) | CA2887706C (https=) |
| DK (5) | DK2914102T3 (https=) |
| ES (4) | ES2748662T3 (https=) |
| FI (2) | FI3939423T3 (https=) |
| IL (5) | IL299887B2 (https=) |
| MX (3) | MX377561B (https=) |
| MY (1) | MY175400A (https=) |
| NO (1) | NO2946162T3 (https=) |
| NZ (3) | NZ724353A (https=) |
| PT (4) | PT3939423T (https=) |
| RU (1) | RU2673156C2 (https=) |
| SG (2) | SG10201707449TA (https=) |
| WO (1) | WO2014071397A2 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| SG10202008003VA (en) | 2011-02-15 | 2020-10-29 | Regeneron Pharma | Humanized m-csf mice |
| FI2892330T3 (fi) * | 2012-09-07 | 2023-03-25 | Univ Yale | Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi |
| MX377561B (es) | 2012-11-05 | 2025-03-10 | Regeneron Pharma | Animales no humanos genéticamente modificados y métodos de uso de los mismos. |
| CN111484999B (zh) | 2013-02-20 | 2024-10-25 | 瑞泽恩制药公司 | 人源化的t细胞共受体的小鼠 |
| EP3699190B9 (en) | 2013-02-22 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Murine cell expressing humanized major histocompatibility complex |
| TR201901782T4 (tr) | 2013-09-23 | 2019-03-21 | Regeneron Pharma | İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar. |
| ES2613379T3 (es) | 2013-10-15 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Animales con IL-15 humanizada |
| RU2671101C1 (ru) | 2013-11-19 | 2018-10-29 | Регенерон Фармасьютикалс, Инк. | Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда |
| CA2929846C (en) | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| CN111690052B (zh) | 2014-04-08 | 2024-06-04 | 瑞泽恩制药公司 | 具有人源化FC-γ受体的非人动物 |
| BR112016024945A2 (pt) | 2014-04-28 | 2017-10-24 | Recombinetics Inc | edição de gene multiplex em suínos |
| EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
| NO2785538T3 (https=) | 2014-05-07 | 2018-08-04 | ||
| MX2016014995A (es) * | 2014-05-19 | 2017-03-31 | Regeneron Pharma | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
| IL287519B2 (en) | 2014-06-19 | 2024-01-01 | Regeneron Pharma | Non-human animals having a humanized programmed cell death 1 gene |
| RU2726446C2 (ru) | 2014-11-24 | 2020-07-14 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3 |
| HUE064960T2 (hu) * | 2014-12-05 | 2024-04-28 | Regeneron Pharma | Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok |
| CN113412818B (zh) | 2014-12-09 | 2022-11-04 | 瑞泽恩制药公司 | 具有人源化分化簇274基因的非人动物 |
| WO2016137841A1 (en) * | 2015-02-26 | 2016-09-01 | William Paterson University Of New Jersey | Transgenic mice |
| EP4248744A3 (en) | 2015-04-06 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
| ES2950399T3 (es) * | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
| WO2017087780A1 (en) | 2015-11-20 | 2017-05-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
| DK3422845T3 (da) | 2016-02-29 | 2021-08-30 | Regeneron Pharma | Gnavere med et humaniseret tmprss-gen |
| SG11201901107RA (en) * | 2016-08-11 | 2019-03-28 | Jackson Lab | Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CN110740641A (zh) * | 2016-11-30 | 2020-01-31 | 杰克逊实验室 | 具有改善的人先天免疫细胞发育的人源化小鼠模型 |
| AU2018224227A1 (en) * | 2017-02-27 | 2019-08-29 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of Retinoschisis |
| CN107115424B (zh) * | 2017-05-09 | 2018-05-29 | 江西樟树市正康医药生物科技有限公司 | 改变酸性体质保钙及清热解毒的中药组合物及制备方法 |
| RU2019140867A (ru) * | 2017-05-12 | 2021-06-15 | Зе Джексон Лаборатори | Nsg мыши, не имеющие mhc класса i и класса ii |
| US20190098879A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use |
| US11712026B2 (en) | 2017-10-18 | 2023-08-01 | The Jackson Laboratory | Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| IL314733A (en) | 2018-03-26 | 2024-10-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| HRP20240999T1 (hr) | 2018-07-16 | 2024-10-25 | Regeneron Pharmaceuticals, Inc. | Glodavački modeli bolesti ditra i njihova upotreba |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN111057721B (zh) * | 2018-10-12 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用 |
| CN111172190B (zh) * | 2018-12-25 | 2021-07-30 | 百奥赛图江苏基因生物技术有限公司 | 人源化细胞因子csf2基因改造非人动物的构建方法及应用 |
| KR102661779B1 (ko) | 2019-04-04 | 2024-04-30 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물 |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| MX2021015122A (es) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Animales no humanos que comprenden un locus de albumina humanizado. |
| WO2021011853A2 (en) * | 2019-07-17 | 2021-01-21 | Yale University | Genetically modified non-human animals and methods of use thereof |
| CN111304246B (zh) * | 2019-12-17 | 2021-05-04 | 百奥赛图江苏基因生物技术有限公司 | 一种人源化细胞因子动物模型、制备方法及应用 |
| IL294356A (en) * | 2020-01-10 | 2022-08-01 | Biocytogen Pharmaceuticals Beijing Co Ltd | Genetically modified non-human animal with human or chimeric mhc protein complex |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| KR20230074758A (ko) | 2020-09-24 | 2023-05-31 | 더 잭슨 래보라토리 | 면역 세포 요법을 평가하기 위한 인간화 마우스 모델 |
| CN118511853A (zh) | 2021-03-31 | 2024-08-20 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| CN116918767A (zh) * | 2022-04-07 | 2023-10-24 | 上海立迪生物技术股份有限公司 | 一种人all小鼠原位pdox模型的建立方法及应用 |
| CN116918766A (zh) * | 2022-04-07 | 2023-10-24 | 上海立迪生物技术股份有限公司 | 一种人aml小鼠原位pdox模型的建立方法及应用 |
| IL318159A (en) | 2022-07-19 | 2025-03-01 | Regeneron Pharma | Genetically modified animal model and its use to model the human immune system |
| KR20260025082A (ko) | 2023-06-16 | 2026-02-23 | 리제너론 파마슈티칼스 인코포레이티드 | 벡터, 유전자 변형 세포, 및 그것을 포함하는 유전자 변형 비인간 동물 |
| US20250255282A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025250495A1 (en) * | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5573930A (en) | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
| WO1988003173A2 (en) | 1986-10-24 | 1988-05-05 | Cetus Corporation | New forms of colony stimulating factor-1 |
| DE3853201T2 (de) | 1987-12-23 | 1995-09-14 | Univ Leland Stanford Junior | Schimäre immunkompromittierende Säugetiere und ihre Verwendung. |
| JP2981486B2 (ja) | 1988-06-14 | 1999-11-22 | メディカル・バイオロジー・インスティチュート | 哺乳動物の免疫系研究方法 |
| JP2935511B2 (ja) * | 1989-10-20 | 1999-08-16 | 忠三 岸本 | ヒトｉｌ―６レセプターの製造方法 |
| US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
| DK0438053T3 (da) | 1990-01-15 | 1999-11-22 | Yeda Res & Dev | Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr |
| US5652373A (en) | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
| WO1991016910A1 (en) | 1990-05-03 | 1991-11-14 | Systemix, Inc. | Human lymphoid tissue in an immunocompromised host |
| US5633426A (en) | 1990-05-25 | 1997-05-27 | Systemix, Inc. | In vivo use of human bone marrow for investigation and production |
| WO1991018615A1 (en) | 1990-05-25 | 1991-12-12 | Systemix, Inc. | Human peripheral blood cells in an immunocompromised host |
| US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
| JPH06505186A (ja) | 1991-02-11 | 1994-06-16 | オマーヤ，アユブ ケー． | 脊髄液駆動式人工器官 |
| EP0517199A1 (en) | 1991-06-04 | 1992-12-09 | Yeda Research And Development Company, Ltd. | Durable engraftment of human tissue and cells in normal mammals |
| WO1993005796A1 (en) | 1991-09-19 | 1993-04-01 | The Scripps Research Institute | Method for producing human antibodies in a non-human animal, and animals therefor |
| EP0539970B1 (en) | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
| US6353150B1 (en) | 1991-11-22 | 2002-03-05 | Hsc Research And Development Limited Partnership | Chimeric mammals with human hematopoietic cells |
| WO1993018144A1 (en) | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
| US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
| US6018096A (en) | 1993-05-03 | 2000-01-25 | Surrogen, Inc. | Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells |
| US5663481A (en) | 1993-08-06 | 1997-09-02 | Mount Sinai Hospital Corporation | Animal model of the human immune system |
| JPH10503092A (ja) | 1994-07-27 | 1998-03-24 | メルク エンド カンパニー インコーポレーテッド | ブラジキニンｂ２受容体が改変されたトランスジェニック非ヒト動物 |
| US6455756B1 (en) | 1994-08-12 | 2002-09-24 | Novartis Ag | Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice |
| US7273753B2 (en) | 1996-08-02 | 2007-09-25 | Center Of Blood Research | Purification and uses of dendritic cells and monocytes |
| IL132164A0 (en) | 1997-04-09 | 2001-03-19 | Chang Lung Ji | Animal model for evaluation of vaccines |
| US6248721B1 (en) | 1997-04-09 | 2001-06-19 | Lung-Ji Chang | Method of using mouse model for evaluation of HIV vaccines |
| GB2337755B (en) * | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| US20030028911A1 (en) | 1999-08-31 | 2003-02-06 | Manley Huang | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| WO2001015521A1 (en) | 1999-08-31 | 2001-03-08 | Genencor International, Inc. | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| AU2066301A (en) * | 1999-12-09 | 2001-06-18 | Human Genome Sciences, Inc. | Il-6 like polynucleotide |
| AU2001290855A1 (en) | 2000-09-14 | 2002-03-26 | Genetrol Biotherapeutics, Inc. | Method and cell composition for screening compounds for anti-inflammatory activity |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP5179697B2 (ja) * | 2001-07-10 | 2013-04-10 | ジョンソン・アンド・ジョンソン・リサーチ・プロプライエタリー・リミテッド | 造血前駆細胞を遺伝的に改変する方法及び改変された細胞の使用 |
| AU2002363322A1 (en) * | 2001-10-26 | 2003-05-19 | Large Scale Biology Corporation | Endothelial cell derived hemotopoietic growth factor |
| EP1452093A4 (en) | 2001-11-15 | 2007-08-15 | Kirin Brewery | CHIMESE NON-MENTAL ANIMAL |
| JPWO2004005496A1 (ja) | 2002-07-05 | 2005-11-04 | 麒麟麦酒株式会社 | 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団 |
| CN101250553A (zh) | 2002-07-13 | 2008-08-27 | 上海医学遗传研究所 | 一种促人血小板生成素表达载体及其构建方法 |
| EP1539946A4 (en) | 2002-09-09 | 2006-03-15 | California Inst Of Techn | METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE |
| EP1418185A1 (en) | 2002-11-11 | 2004-05-12 | Aventis Pharma Deutschland GmbH | Use of EDG2 receptor in an animal model of heart failure |
| CA2507882A1 (en) | 2002-12-16 | 2004-07-22 | Genentech, Inc. | Transgenic mice expressing human cd20 |
| JP4912144B2 (ja) * | 2003-03-12 | 2012-04-11 | ジェネンテック， インコーポレイテッド | 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用 |
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| ES2463476T3 (es) | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Método para generar un ratón homocigótico para una modificación genética |
| US7759541B2 (en) * | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
| DK2019683T4 (da) | 2006-04-25 | 2022-08-29 | Univ California | Indgivelse af vækstfaktorer til behandling af CNS-lidelser |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| WO2008060360A2 (en) | 2006-09-28 | 2008-05-22 | Surmodics, Inc. | Implantable medical device with apertures for delivery of bioactive agents |
| WO2008069659A1 (en) | 2006-12-05 | 2008-06-12 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Improved xenogenic immune system in a non-human mammal |
| WO2008153742A2 (en) | 2007-05-23 | 2008-12-18 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression |
| GB0718029D0 (en) | 2007-09-14 | 2007-10-24 | Iti Scotland Ltd | Two step cluster deletion and humanisation |
| WO2009042917A1 (en) | 2007-09-28 | 2009-04-02 | The General Hospital Corporation | Methods and compositions for antibody production |
| WO2009097468A2 (en) | 2008-01-29 | 2009-08-06 | Kliman Gilbert H | Drug delivery devices, kits and methods therefor |
| RU2539099C2 (ru) * | 2009-04-13 | 2015-01-10 | Апцет Гмбх Унд Ко.Кг | Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей |
| EP2448967B1 (en) | 2009-06-29 | 2015-04-15 | Ilya B. Leskov | Non-human mammal model of human hematopoietic cancer |
| CN102725400A (zh) * | 2009-06-29 | 2012-10-10 | 麻省理工学院 | 制造人源化的非人类哺乳动物的方法 |
| RU2425880C2 (ru) | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| CA2784953C (en) * | 2009-12-21 | 2018-05-22 | Regeneron Pharmaceuticals, Inc. | Humanized fc.gamma.r mice |
| EP2618656B1 (en) | 2010-09-20 | 2018-06-20 | Yale University, Inc. | HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE |
| WO2012051572A1 (en) | 2010-10-15 | 2012-04-19 | Massachusetts Institute Of Technology | A humanized non-human mammal model of malaria and uses thereof |
| SG10202008003VA (en) | 2011-02-15 | 2020-10-29 | Regeneron Pharma | Humanized m-csf mice |
| CN108866101A (zh) * | 2011-10-28 | 2018-11-23 | 瑞泽恩制药公司 | 人源化il-6和il-6受体 |
| FI2892330T3 (fi) | 2012-09-07 | 2023-03-25 | Univ Yale | Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi |
| MX377561B (es) | 2012-11-05 | 2025-03-10 | Regeneron Pharma | Animales no humanos genéticamente modificados y métodos de uso de los mismos. |
| TR201901782T4 (tr) | 2013-09-23 | 2019-03-21 | Regeneron Pharma | İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar. |
| ES2613379T3 (es) | 2013-10-15 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Animales con IL-15 humanizada |
| MX2016014995A (es) | 2014-05-19 | 2017-03-31 | Regeneron Pharma | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
| ES2950399T3 (es) | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
-
2013
- 2013-11-05 MX MX2019015882A patent/MX377561B/es active IP Right Grant
- 2013-11-05 FI FIEP21176673.8T patent/FI3939423T3/fi active
- 2013-11-05 US US14/072,626 patent/US9901082B2/en active Active
- 2013-11-05 SG SG10201707449TA patent/SG10201707449TA/en unknown
- 2013-11-05 CN CN201810319216.2A patent/CN108401987B/zh active Active
- 2013-11-05 PT PT211766738T patent/PT3939423T/pt unknown
- 2013-11-05 IL IL299887A patent/IL299887B2/en unknown
- 2013-11-05 KR KR1020217020816A patent/KR102402806B1/ko active Active
- 2013-11-05 EP EP19176252.5A patent/EP3556206B1/en active Active
- 2013-11-05 MX MX2015005654A patent/MX370856B/es active IP Right Grant
- 2013-11-05 RU RU2015121195A patent/RU2673156C2/ru active
- 2013-11-05 MY MYPI2015000877A patent/MY175400A/en unknown
- 2013-11-05 DK DK13811637.1T patent/DK2914102T3/en active
- 2013-11-05 KR KR1020227017372A patent/KR102458016B1/ko active Active
- 2013-11-05 KR KR1020157011974A patent/KR102275412B1/ko active Active
- 2013-11-05 PT PT191762525T patent/PT3556206T/pt unknown
- 2013-11-05 EP EP13811637.1A patent/EP2914102B1/en active Active
- 2013-11-05 DK DK24161280.3T patent/DK4389764T3/da active
- 2013-11-05 DK DK21176673.8T patent/DK3939423T3/da active
- 2013-11-05 DK DK19176252.5T patent/DK3556206T3/da active
- 2013-11-05 AU AU2013337242A patent/AU2013337242B2/en active Active
- 2013-11-05 IL IL311744A patent/IL311744B2/en unknown
- 2013-11-05 NZ NZ724353A patent/NZ724353A/en unknown
- 2013-11-05 NZ NZ749626A patent/NZ749626A/en unknown
- 2013-11-05 WO PCT/US2013/068569 patent/WO2014071397A2/en not_active Ceased
- 2013-11-05 FI FIEP24161280.3T patent/FI4389764T3/fi active
- 2013-11-05 KR KR1020227036338A patent/KR102649893B1/ko active Active
- 2013-11-05 CN CN201380056429.6A patent/CN104918483B/zh active Active
- 2013-11-05 EP EP17184813.8A patent/EP3308641B1/en active Active
- 2013-11-05 KR KR1020247008928A patent/KR102768101B1/ko active Active
- 2013-11-05 JP JP2015540872A patent/JP6422441B2/ja active Active
- 2013-11-05 ES ES17184813T patent/ES2748662T3/es active Active
- 2013-11-05 PT PT138116371T patent/PT2914102T/pt unknown
- 2013-11-05 PT PT171848138T patent/PT3308641T/pt unknown
- 2013-11-05 ES ES13811637.1T patent/ES2655442T3/es active Active
- 2013-11-05 DK DK17184813.8T patent/DK3308641T3/da active
- 2013-11-05 SG SG11201502685XA patent/SG11201502685XA/en unknown
- 2013-11-05 CA CA2887706A patent/CA2887706C/en active Active
- 2013-11-05 CN CN202210388378.8A patent/CN114766432B/zh active Active
- 2013-11-05 NZ NZ631614A patent/NZ631614A/en unknown
- 2013-11-05 EP EP21176673.8A patent/EP3939423B1/en active Active
- 2013-11-05 EP EP24161280.3A patent/EP4389764B1/en active Active
- 2013-11-05 ES ES19176252T patent/ES2884598T3/es active Active
- 2013-11-05 ES ES21176673T patent/ES2983031T3/es active Active
-
2014
- 2014-02-18 NO NO14705284A patent/NO2946162T3/no unknown
-
2015
- 2015-04-27 IL IL238478A patent/IL238478B/en active IP Right Grant
- 2015-05-04 MX MX2020012427A patent/MX2020012427A/es unknown
-
2016
- 2016-06-24 US US15/192,903 patent/US9986724B2/en active Active
-
2017
- 2017-11-06 US US15/804,989 patent/US10785968B2/en active Active
-
2018
- 2018-04-26 IL IL25896818A patent/IL258968B/en active IP Right Grant
- 2018-10-16 JP JP2018194712A patent/JP6772234B2/ja active Active
-
2019
- 2019-07-03 AU AU2019204775A patent/AU2019204775B2/en active Active
- 2019-10-23 IL IL270124A patent/IL270124B2/en unknown
-
2020
- 2020-08-21 US US17/000,140 patent/US11778995B2/en active Active
- 2020-09-30 JP JP2020165884A patent/JP7105844B2/ja active Active
-
2022
- 2022-01-18 AU AU2022200302A patent/AU2022200302B2/en active Active
- 2022-07-12 JP JP2022111649A patent/JP7579304B2/ja active Active
-
2023
- 2023-08-21 US US18/236,218 patent/US20240099278A1/en active Pending
-
2024
- 2024-10-25 JP JP2024187836A patent/JP2025010204A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534819A5 (https=) | ||
| Shultz et al. | Humanized mice for immune system investigation: progress, promise and challenges | |
| Meraz et al. | An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses | |
| Pham et al. | Preclinical models of pancreatic ductal adenocarcinoma and their utility in immunotherapy studies | |
| Dawson et al. | Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells | |
| Morton et al. | Humanized mouse xenograft models: narrowing the tumor–microenvironment gap | |
| Das et al. | Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice | |
| FI3939423T3 (fi) | Geneettisesti muokattuja ei-ihmiseläimiä ja niiden käyttömenetelmiä | |
| JP2022105531A (ja) | 遺伝学的に修飾された非ヒト動物およびその使用法 | |
| Karnik et al. | Emerging preclinical applications of humanized mouse models in the discovery and validation of novel immunotherapeutics and their mechanisms of action for improved cancer treatment | |
| JP2018500012A5 (https=) | ||
| JP2014110814A5 (https=) | ||
| Zeng et al. | Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells | |
| JP2012532598A5 (https=) | ||
| Kumari et al. | Humanized mouse models for immuno‐oncology drug discovery | |
| Dhenni et al. | Macrophages direct location-dependent recall of B cell memory to vaccination | |
| Chung et al. | Co-transplantation of human fetal thymus, bone and CD34+ cells into young adult immunodeficient NOD/SCID IL2Rγnull mice optimizes humanized mice that mount adaptive antibody responses | |
| Ren et al. | Translational models in glioma immunotherapy research | |
| Spits | New models of human immunity | |
| JP2025503669A (ja) | 改変されたｔ細胞を組み込むシステム及び方法 | |
| EP4346396A1 (en) | Animal models and therapeutic molecules | |
| US11913026B2 (en) | Bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibodies, methods for production thereof and methods of treatment | |
| Yanagawa et al. | Development of a humanized mouse model to analyze antibodies specific for human leukocyte antigen (HLA) | |
| Jantscheff et al. | Mouse-derived isograft (MDI) in vivo tumor models I. spontaneous sMDI models: Characterization and cancer therapeutic approaches | |
| Chung et al. | Transplantation of human spleen into immunodeficient NOD/SCID IL2Rγnull mice generates humanized mice that improve functional B cell development |